194 related articles for article (PubMed ID: 22044266)
21. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation.
Miller MA; Mikula H; Luthria G; Li R; Kronister S; Prytyskach M; Kohler RH; Mitchison T; Weissleder R
ACS Nano; 2018 Dec; 12(12):12814-12826. PubMed ID: 30550257
[TBL] [Abstract][Full Text] [Related]
22. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
23. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
24. Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3.
Zhu JH; Yuan Y; Li D; Liao SJ; Zhou YH; Wang Q; Shu Y; Yan B; Wei JJ; Sun R; Zhang GM; Feng ZH
Cancer Sci; 2012 Jul; 103(7):1319-26. PubMed ID: 22494046
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.
Vielhauer GA; Swink M; Parelkar NK; Lajiness JP; Wolfe AL; Boger D
Cancer Biol Ther; 2013 Jun; 14(6):527-36. PubMed ID: 23760495
[TBL] [Abstract][Full Text] [Related]
26. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.
Bajjuri KM; Liu Y; Liu C; Sinha SC
ChemMedChem; 2011 Jan; 6(1):54-9. PubMed ID: 21154805
[No Abstract] [Full Text] [Related]
27. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
29. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
31. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
[TBL] [Abstract][Full Text] [Related]
32. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
[TBL] [Abstract][Full Text] [Related]
33. Tumor vasculature-targeting PEGylated peptide-drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis.
Hao T; Fu Y; Yang Y; Yang S; Liu J; Tang J; Ridwan KA; Teng Y; Liu Z; Li J; Guo N; Yu P
Eur J Med Chem; 2021 Jul; 219():113430. PubMed ID: 33865152
[TBL] [Abstract][Full Text] [Related]
34. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis.
Lin Y; Wei C; Liu Y; Qiu Y; Liu C; Guo F
Cancer Sci; 2013 Sep; 104(9):1217-25. PubMed ID: 23691974
[TBL] [Abstract][Full Text] [Related]
35. Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.
Liu C; Wang J; Zheng Y; Zhu Y; Zhou Z; Liu Z; Lin C; Wan Y; Wen Y; Liu C; Yuan M; Zeng YA; Yan Z; Ge G; Chen J
Oncogene; 2022 Aug; 41(34):4091-4103. PubMed ID: 35854065
[TBL] [Abstract][Full Text] [Related]
36. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
[TBL] [Abstract][Full Text] [Related]
37. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
38. Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
Liu ZY; Tang ML; Ning JF; Hao YP; Zhou L; Sun X
Eur J Med Chem; 2020 May; 193():112194. PubMed ID: 32203786
[TBL] [Abstract][Full Text] [Related]
39. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Brennen WN; Rosen DM; Chaux A; Netto GJ; Isaacs JT; Denmeade SR
Prostate; 2014 Sep; 74(13):1308-19. PubMed ID: 25053236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
